Digene's Hybrid Capture Worthy Of "Signal Amplification" Label - FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
The FDA Microbiology Devices Panel's unanimous recommendation May 20 to allow Digene to state that its Hybrid Capture cytomegalovirus DNA test performs "signal amplification" could open the door for other technologies to pursue the same terminology.